Compound A Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
vs
Compound B Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
Molecular weight
2174.69 g/mol
663.43 g/mol
Half-life
~4-6 hours (estimated, limited PK data)
~30-45 minutes (IV); ~2-4 hours (SubQ)
Admin routes
subcutaneous intraperitoneal
intravenous subcutaneous oral (NMN/NR precursors) transdermal
Research areas
Metabolic regulation Exercise performance Longevity / aging Insulin sensitivity Obesity Type 2 diabetes PCOS Adrenal physiology
Anti-aging / longevity Mitochondrial function Neuroprotection Addiction recovery DNA repair Metabolic health Inflammation modulation
Typical dosing
5000–10000 mcg · 3-5x weekly · 4-8 weeks
50000–500000 mcg · 1-2x weekly (SubQ) or monthly (IV) · Ongoing / maintenance protocol
FDA status
Not FDA-approved. Not on the 503A bulks list and not in any FDA interim category. An FDA advisory committee (PCAC) recommended it for the 503A bulks list on 2026-07-23 — for no evaluated indication; FDA has not adopted that recommendation and compounding MOTS-c is not permitted.
Not FDA-approved as drug. NAD+ precursors (NMN, NR) available OTC as dietary supplements. IV/SubQ NAD+ available through clinics and compounding pharmacies
WADA status
Not explicitly listed
Not prohibited
